The battle to find new antibiotics to replace those that are becoming increasingly ineffective against bacteria has been boosted by the launch of a $165m venture fund set up by Novo Holdings to address the early-stage funding gap.
The REPAIR (Replenishing and Enabling the Pipeline for Anti-Infective Resistance) Impact Fund will invest $20–40m per year over three–five years...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?